Health Canada Approves Zepbound as First GLP-1 Treatment for Obstructive Sleep Apnea in Adults with Obesity

Health Canada has approved the weight loss medication Zepbound for the treatment of obstructive sleep apnea in adults living with obesity, marking a significant advancement in the management of one of the country’s most common sleep disorders.

The approval, granted on June 11, makes Zepbound the first and only GLP-1 based medication in Canada specifically authorized to treat obstructive sleep apnea in adults with obesity. The decision expands the drug’s role beyond weight management and offers patients a new therapeutic option alongside existing treatments.

Obstructive sleep apnea is a condition in which a person’s breathing repeatedly stops and starts during sleep because the upper airway becomes blocked. The blockage often occurs when the muscles of the throat relax excessively or when excess fatty tissue narrows the airway. Left untreated, the condition can lead to serious health complications, including excessive daytime fatigue, high blood pressure, heart disease, stroke, and other cardiovascular problems.

Medical experts note that obesity is one of the strongest risk factors for obstructive sleep apnea, making weight reduction an important part of long term treatment.

The active ingredient in Zepbound is tirzepatide, a medication that works by activating both GLP-1 and GIP hormone receptors. These hormones help regulate appetite and blood sugar levels, allowing patients to consume fewer calories and achieve meaningful weight loss.

Tirzepatide is manufactured by Eli Lilly and is also used in its diabetes medication Mounjaro. The company’s products compete with Novo Nordisk’s semaglutide based medications, including Ozempic and Wegovy, which are widely prescribed for diabetes and weight management.

Health Canada said Zepbound is intended for adults with obesity, defined as having a body mass index of 30 kilograms per square metre or higher. The medication is administered as a once weekly injection and should be used in combination with a reduced calorie diet and increased physical activity to achieve the best results.

Health officials emphasized that the approval does not replace Continuous Positive Airway Pressure therapy, commonly known as CPAP, which remains the standard first line treatment for patients with moderate to severe obstructive sleep apnea.

Patients currently using CPAP are advised not to discontinue their therapy without first consulting their healthcare provider, even if they begin treatment with Zepbound.

The approval follows successful Phase Three clinical trials involving adults diagnosed with both obesity and obstructive sleep apnea.

The studies produced encouraging results. Participants who were not using CPAP therapy experienced an average reduction of 25 breathing interruptions per hour after receiving tirzepatide, compared with only five fewer interruptions among patients receiving a placebo.

Among patients who continued using CPAP during the trials, those treated with tirzepatide recorded an average reduction of 29 breathing interruptions per hour, while participants receiving a placebo experienced an average reduction of only six interruptions.

Sleep specialists say these improvements could represent a significant reduction in disease severity for many patients.

Experts explain that mild obstructive sleep apnea typically involves between five and fourteen breathing interruptions per hour of sleep. Moderate cases range from fifteen to thirty interruptions, while severe cases involve more than thirty breathing interruptions every hour.

A reduction of approximately twenty five to twenty nine events per hour could potentially move many patients from the severe category into a lower risk classification, improving both sleep quality and overall health.

Specialists have welcomed the approval as an important addition to the growing range of treatment options available for patients with obesity related sleep apnea.

Researchers also believe the findings may encourage further investigation into whether similar medications could benefit patients with sleep apnea who are not obese. While some physicians have observed improvements among patients using other GLP-1 medications, comprehensive clinical evidence remains limited.

Scientists are particularly interested in determining whether tirzepatide improves sleep apnea solely through weight loss or whether it may also have direct effects on the muscles and tissues surrounding the upper airway.

Like other medications in the GLP-1 drug class, Zepbound can cause side effects. The most commonly reported reactions include nausea, vomiting, diarrhea, and constipation. Although uncommon, more serious complications may include inflammation of the pancreas, bowel obstruction, and gallstones.

Healthcare professionals emphasize that treatment decisions should always be individualized after discussing the potential benefits and risks with patients.

The approval of Zepbound represents another milestone in the evolving treatment of obesity related conditions. By addressing both excess weight and obstructive sleep apnea, the medication may help improve quality of life while reducing the long term health risks associated with untreated sleep disorders.

Medical experts expect the new approval to provide physicians with greater flexibility when developing treatment plans for patients living with obesity and obstructive sleep apnea, while continuing to stress that healthy lifestyle changes and appropriate medical supervision remain essential components of successful long term care.

Courtesy: globalnews